Payment overview · 2025
General Payments
$181.13
9 reported records · 6 companies
Healthcare provider profile · identity verified
Jeffrey Jonathan Lynds, MD
Allopathic & Osteopathic Physicians|Family Medicine · HOULTON, ME · NPI 1851554075
Verified facts
What the public records show
CMS Open Payments records show Jeffrey Jonathan Lynds, MD received $181.13 in general payments during 2025 across 9 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $53.00 | 29.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.60 | 24.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.40 | 13.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.43 | 12.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.82 | 12.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.88 | 7.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $181.13 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $53.00 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.60 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.60 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.40 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $22.82 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.88 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $13.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 127 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
127 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
97 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 496 | 147 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 272 | 75 |
| Lisinopril | Lisinopril | 269 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 250 | 76 |
| Omeprazole | Omeprazole | 229 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 209 | 71 |
| Losartan Potassium | Losartan Potassium | 193 | 59 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 192 | 46 |
| Gabapentin | Gabapentin | 181 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 170 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 158 | 51 |
| Prednisone | Prednisone | 156 | 106 |
| Tramadol Hcl | Tramadol Hcl | 148 | 47 |
| Metformin Hcl | Metformin Hcl | 144 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 40 |
| Trulicity | Dulaglutide | 131 | 22 |
| Jardiance | Empagliflozin | 127 | 29 |
| Simvastatin | Simvastatin | 124 | 39 |
| Furosemide | Furosemide | 105 | 32 |
| Eliquis | Apixaban | 97 | 29 |
| Oxycodone Hcl | Oxycodone Hcl | 91 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 83 | 16 |
| Famotidine | Famotidine | 78 | 25 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 72 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 20 |
| Trazodone Hcl | Trazodone Hcl | 65 | 18 |
| Celecoxib | Celecoxib | 63 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 25 |
| Farxiga | Dapagliflozin Propanediol | 61 | 12 |
| Metformin Hcl Er | Metformin Hcl | 60 | 18 |
| Allopurinol | Allopurinol | 58 | 17 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 58 | 48 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 57 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 15 |
| Alprazolam | Alprazolam | 56 | suppressed |
| Pregabalin | Pregabalin | 56 | 13 |
| Sertraline Hcl | Sertraline Hcl | 52 | 16 |
| Carvedilol | Carvedilol | 51 | 19 |
| Lorazepam | Lorazepam | 51 | 11 |
| Alendronate Sodium | Alendronate Sodium | 49 | 14 |
| Montelukast Sodium | Montelukast Sodium | 47 | 18 |
| Potassium Chloride | Potassium Chloride | 47 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 13 |
| Meloxicam | Meloxicam | 46 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 15 |
| Bupropion Xl | Bupropion Hcl | 44 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 44 | 16 |
| Clonazepam | Clonazepam | 42 | suppressed |
| Xarelto | Rivaroxaban | 42 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 11 |
| Ibuprofen | Ibuprofen | 39 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Azithromycin | Azithromycin | 38 | 34 |
| Nortriptyline Hcl | Nortriptyline Hcl | 36 | suppressed |
| Atenolol | Atenolol | 35 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 31 |
| Ezetimibe | Ezetimibe | 33 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Methadone Hcl | Methadone Hcl | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | 12 |
| Risperidone | Risperidone | 28 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 28 | 19 |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Xtampza Er | Oxycodone Myristate | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 15 |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 17 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 11 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Humulin R U-500 | Insulin Regular, Human | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $181.13 · 9 records | AstraZeneca Pharmaceuticals LP | BREZTRI, JARDIANCE, Kerendia, NURTEC ODT, Ozempic, PAXLOVID, Rybelsus, The Cologuard Plus Collection Kit | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error